基于PTCy的移植物抗宿主病预防方案用于全相合同胞供者异基因造血细胞移植
这项回顾性研究纳入2010年1月至2023年1月接受外周血干细胞移植的413例全相合同胞供者移植患者,分为4组比较不同GVHD预防方案。含PTCy方案较含CNI+MTX(或MMF)方案显著降低2-4级和3-4级急性GVHD及中重度慢性GVHD,不增加复发风险,降低非复发死亡,改善GRFS(HR 0.4,P<.001)和总生存,但血流感染增加;PTCy基础上加ATG未进一步改善GRFS,且csCMV和csEBV再激活发生率更高、NRM数值上升。
要点
- 含PTCy方案较含CNI+MTX(或MMF)方案显著降低2-4级和3-4级急性GVHD及中重度慢性GVHD。
- PTCy不增加复发风险,降低非复发死亡,改善GRFS(HR 0.4,P<.001)和总生存,但血流感染增加。
- PTCy加ATG未进一步改善GRFS,csCMV和csEBV再激活更高,NRM数值上升。
核心结论
- 在外周血干细胞移植的全相合同胞供者移植中,含PTCy方案似乎显著改善GRFS。
- PTCy基础上加ATG增加csCMV和csEBV再激活,且未进一步改善GRFS。
- 需要前瞻性试验和PTCy剂量优化。
研究设计与样本
- 回顾性研究,纳入2010年1月至2023年1月接受外周血干细胞移植的413例全相合同胞供者造血细胞移植患者。
- 分为4组:I组(钙调磷酸酶抑制剂[CNI]+甲氨蝶呤[MTX]或吗替麦考酚酯[MMF])、II组(CNI+MTX或MMF+抗胸腺细胞球蛋白[ATG])、III组(PTCy+ATG+CNI)、IV组(PTCy+CNI+MMF)。
主要发现
- 与含CNI+MTX(或MMF)方案相比,PTCy与2-4级和3-4级急性GVHD及中重度慢性GVHD显著降低相关。
- PTCy未增加复发风险;PTCy降低非复发死亡,改善GRFS(风险比0.4;P<.001)。
- PTCy还与总生存改善相关。
- PTCy组血流感染增加。
- PTCy基础上加ATG未进一步改善GRFS,与csCMV和csEBV再激活发生率更高相关,NRM数值上升。
关键数值与推荐
- GRFS:风险比0.4;P<.001(PTCy方案对比含CNI+MTX或MMF方案)。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文为回顾性研究。
- 原文指出需要前瞻性试验和PTCy剂量优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Posttransplant cyclophosphamide (PTCy) is a promising graft-versus-host disease (GVHD) prophylaxis in haploidentical and matched unrelated donor hematopoietic stem cell transplantation (HSCT), but its role in matched sibling donor (MSD) transplants remains unclear. We conducted a retrospective study of 413 MSD-HSCT patients receiving peripheral blood stem cell (PBSC) grafts from January 2010 to January 2023. Patients were categorized into 4 groups: group I (calcineurin inhibitor [CNI] + methotrexate [MTX] or mycophenolate mofetil [MMF]), group II (CNI + MTX or MMF + antithymocyte globulin [ATG]), group III (PTCy + ATG + CNI), and group IV (PTCy + CNI + MMF). PTCy was associated with a significant reduction in grade 2- 4 and grade 3-4 acute GVHD and moderate-to-severe chronic GVHD compared with CNI + MTX (or MMF)-containing regimens. PTCy did not increase relapse risk; PTCy reduced nonrelapse mortality, leading to improved GVHD-free/relapse-free survival (GRFS; Hazard Ratio, 0.4; P < .001). PTCy was also associated with improved overall survival. Bloodstream infections were increased with PTCy. The addition of ATG to PTCy did not further improve GRFS and was associated with a higher incidence of clinically significant cytomegalovirus (csCMV) and Epstein-Barr virus (csEBV) reactivation and a numerical increase in NRM. PTCy significantly appeared to improve GRFS in the MSD setting using PBSC grafts. The addition of ATG to PTCy increases csCMV and csEBV reactivation without further improving GRFS. Prospective trials and PTCy dose optimization are warranted.
引用
- Desai N, Altareb M, Remberger M, et al. PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation. Blood Adv. 2025. PMID: 39565954. doi:10.1182/bloodadvances.2024014781
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。